Summary of Study ST000916
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000633. The data can be accessed directly via it's Project DOI: 10.21228/M8V961 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST000916 |
| Study Title | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma |
| Study Type | Lipidomics Study |
| Study Summary | The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepatitis (NASH), and cirrhosis. Recognition and timely diagnosis of these different stages, particularly NASH, is important for both potential reversibility and limitation of complications. Liver biopsy remains the clinical standard for definitive diagnosis. Diagnostic tools minimizing the need for invasive procedures or that add information to histologic data are important in novel management strategies for the growing epidemic of NAFLD. We describe an 'omics' approach to detecting a reproducible signature of lipid metabolites, aqueous intracellular metabolites, SNPs, and mRNA transcripts in a double-blinded study of patients with different stages of NAFLD that involves profiling liver biopsies, plasma, and urine samples. Using linear discriminant analysis, a panel of 20 plasma metabolites that includes glycerophospholipids, sphingolipids, sterols, and various aqueous small molecular weight components involved in cellular metabolic pathways, can be used to differentiate between NASH and steatosis. This identification of differential biomolecular signatures has the potential to improve clinical diagnosis and facilitate therapeutic intervention of NAFLD. |
| Institute | LIPID MAPS |
| Department | Bioengineering |
| Last Name | Fahy |
| First Name | Eoin |
| Address | 9500 Gilman, La Jolla, CA, 92093, USA |
| efahy@ucsd.edu | |
| Phone | 858-534-4076 |
| Submit Date | 2018-01-14 |
| Publications | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340319/ |
| Raw Data Available | Yes |
| Analysis Type Detail | GC-MS/LC-MS |
| Release Date | 2018-04-05 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR000633 |
| Project DOI: | doi: 10.21228/M8V961 |
| Project Title: | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic |
| Project Type: | Lipidomics Study |
| Project Summary: | The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepatitis (NASH), and cirrhosis. Recognition and timely diagnosis of these different stages, particularly NASH, is important for both potential reversibility and limitation of complications. Liver biopsy remains the clinical standard for definitive diagnosis. Diagnostic tools minimizing the need for invasive procedures or that add information to histologic data are important in novel management strategies for the growing epidemic of NAFLD. We describe an 'omics' approach to detecting a reproducible signature of lipid metabolites, aqueous intracellular metabolites, SNPs, and mRNA transcripts in a double-blinded study of patients with different stages of NAFLD that involves profiling liver biopsies, plasma, and urine samples. Using linear discriminant analysis, a panel of 20 plasma metabolites that includes glycerophospholipids, sphingolipids, sterols, and various aqueous small molecular weight components involved in cellular metabolic pathways, can be used to differentiate between NASH and steatosis. This identification of differential biomolecular signatures has the potential to improve clinical diagnosis and facilitate therapeutic intervention of NAFLD. |
| Institute: | University of California, San Diego |
| Department: | Bioengineering |
| Last Name: | Fahy |
| First Name: | Eoin |
| Address: | 9500 Gilman, La Jolla, CA, 92093, USA |
| Email: | efahy@ucsd.edu |
| Phone: | 858-534-4076 |
| Funding Source: | NIGMS Grant GM U54069338 |
| Publications: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340319/ |
| Contributors: | LIPID MAPS Consortium |
